Molecular Targeted Therapy Industry Projected to Experience Accelerated Growth by 2029

 Save 20% on All Global Market Reports With Code ONLINE20 — Gain Insights Into Tariffs, Inflation, and Industry Trends

 

 What Is the Expected Market Growth Rate for the Molecular Targeted Therapy Market?
 The molecular targeted therapy market size has grown strongly in recent years. It will grow from $65.78 billion in 2024 to $71.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to the increasing prevalence of chronic diseases, rising demand for personalized medicine, growing use of biomarkers in drug development, increasing adoption of monoclonal antibodies, and rising approvals for oncology therapies.
 
 The molecular targeted therapy market size is expected to see strong growth in the next few years. It will grow to $99.4 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to growing investment in cancer research, increasing demand for targeted immunotherapies, expanding clinical trial activities in precision medicine, increasing use of companion diagnostics, and growing healthcare access in emerging economies. Major trends in the forecast period include technological advancements in genomics, innovation in drug delivery systems, increased investment in research and development, developments in molecular diagnostics, and adoption of AI technology for therapy discovery.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24609&type=smp
 
 What Are the Major Drivers Influencing the Molecular Targeted Therapy Market?
 The rise of personalized medicine is expected to propel the growth of the molecular targeted therapy market going forward. Personalized medicine is a healthcare approach that customizes treatment and prevention based on an individual’s genetic profile, lifestyle, and environmental factors. Personalized medicine is rising due to increasing genetic data availability, enabling treatments tailored to individual genomes for better efficacy and fewer side effects. Personalized medicine supports molecular targeted therapy by analyzing a patient’s tumor for specific genetic mutations or biomarkers, allowing for the selection of therapies that directly target those abnormalities. This approach improves treatment precision and reduces harm to healthy tissues. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the rise of personalized medicine is driving the growth of the molecular targeted therapy market.
 
 Which Are the Leading Segments in the Molecular Targeted Therapy Market by Revenue?
 The molecular targeted therapy market covered in this report is segmented — 
 
 1) By Therapy Type: Monoclonal Antibodies, Small Molecule Inhibitors, Gene Therapy, Cell Therapy
 2) By Mode Of Administration: Oral, Injectable, Topical, Intravenous
 3) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Other Applications
 4) By End-User: Hospitals, Clinics, Research Laboratories, Diagnostic Centers
 
 Subsegments:
 1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
 2) By Small Molecule Inhibitors: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors, Mechanistic Target Of Rapamycin (mTOR) Inhibitors
 3) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing
 4) By Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TILs) Therapy, Dendritic Cell Therapy
 
 What Are the Significant Trends in the Molecular Targeted Therapy Market Across Regions?
 Major companies operating in the molecular targeted therapy market are focusing on developing advanced products such as small molecule inhibitors to improve patient outcomes in various cancers and chronic diseases. Small molecule inhibitors are tiny compounds that can easily penetrate cells and inhibit specific proteins that drive disease. For instance, in January 2025, Amgen Inc., a US-based pharmaceutical company, introduced Lumakras (sotorasib) in combination with Vectibix (panitumumab), which received approval from the US Food and Drug Administration (FDA), a US-based government organization. It is designed for adult patients with KRAS G12C-mutated metastatic colorectal cancer who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as determined by an FDA-approved test. This approval is based on the Phase 3 CodeBreaK 300 trial, which showed that the combination more than doubled progression-free survival compared to the investigated standard of care, making it the first targeted therapy to show such benefit in this chemorefractory patient population.
 
 Who Are the Leading Players in the Molecular Targeted Therapy Market?
 Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc. 
 
 Get the full molecular targeted therapy market report here:
 https://www.thebusinessresearchcompany.com/report/molecular-targeted-therapy-global-market-report
 
 What Are the Opportunities and Challenges for Molecular Targeted Therapy Market Across Regions?
 North America was the largest region in the molecular targeted therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company